Evidence map›Paper›PMID 40527969›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2025

PET imaging with [¹¹C]CHDI-00485180-R, designed as radioligand for aggregated mutant huntingtin, in people with Huntington's disease.

Aline Delva, Michel Koole, Kim Serdons, Guy Bormans, Mette Skinbjerg, Vinod Khetarpal, Longbin Liu, Jonathan Bard, Robert Doot, John H Warner and 5 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03810898 (First-in-Human Adaptive Study to Investigate the Binding and Kinetic Properties of Two Novel PET Ligands and Their Suitability for Quantification of Aggregated Mutant Huntingtin in the Brains of Huntington's Disease Gene-Expansion Carriers), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03810898 early_phase1terminatednot on this map

First-in-Human Adaptive Study to Investigate the Binding and Kinetic Properties of Two Novel PET Ligands and Their Suitability for Quantification of Aggregated Mutant Huntingtin in the Brains of Huntington's Disease Gene-Expansion Carriers

TypeinterventionalSponsorCHDI Foundation, Inc.Ran2021 to 2023Enrolled24ConditionsHuntington DiseaseArmsRadioligand [¹¹C]CHDI-00485180-R, Radioligand [¹¹C]CHDI-00485626
3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. In Vivo PET Imaging of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
  2. Preclinical evaluation of [Journal of molecular medicine (Berlin, Germany) · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Aline DelvaDepartment of Neurosciences, KU Leuven, Leuven, Belgium. aline.delva@uzleuven.be.ORCID 0000-0001-8497-2314
Michel KooleDepartment of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Kim SerdonsDivision of Nuclear Medicine, University Hospitals Leuven, Leuven, Belgium.
Guy BormansDepartment of Pharmaceutical and Pharmacological Sciences, KU Leuven, Leuven, Belgium.
Mette SkinbjergCHDI Management, CHDI Foundation Inc, Princeton, NJ, USA.
Vinod KhetarpalCHDI Management, CHDI Foundation Inc, Princeton, NJ, USA.
Longbin LiuCHDI Management, CHDI Foundation Inc, Princeton, NJ, USA.
Jonathan BardCHDI Management, CHDI Foundation Inc, Princeton, NJ, USA.
Robert DootCHDI Management, CHDI Foundation Inc, Princeton, NJ, USA.
John H WarnerCHDI Management, CHDI Foundation Inc, Princeton, NJ, USA.
Swati SatheCHDI Management, CHDI Foundation Inc, Princeton, NJ, USA.
Cristina SampaioCHDI Management, CHDI Foundation Inc, Princeton, NJ, USA.
Andrew WoodCHDI Management, CHDI Foundation Inc, Princeton, NJ, USA.
Koen Van Laere *Department of Imaging and Pathology, KU Leuven, Leuven, Belgium.
Wim Vandenberghe *Department of Neurosciences, KU Leuven, Leuven, Belgium.

Funding

CHDI Foundation CHDI FoundationFund for Scientific Research Flanders FR-1106521N
6 · The paper itself

Abstract

purpose[

methodsA total of 12 pwHD (53.7 ± 6.9y, 5 M/ 7 F, Shoulson-Fahn stage 2) and 12 healthy controls (HC; six young [26.8 ± 3.2y], 2 M/ 4 F; six age-matched [53.7 ± 6.1y],2 M/ 4 F) were included. We conducted dynamic 90 min [

resultsV

conclusion[ REGISTRATION: EudraCT 2018-001862-41 clinicaltrials.gov NCT03810898  https://clinicaltrials.gov/study/NCT03810898?term=NCT03810898&rank=1.

Indexed as

Huntingtin ProteinHuntington DiseaseMutationPositron-Emission TomographyRadiopharmaceuticalsAdultBrainCarbon RadioisotopesCase-Control StudiesFemaleHumansLigandsMaleMiddle AgedTissue DistributionCarbon RadioisotopesHTT protein, humanHuntingtin ProteinLigandsRadiopharmaceuticals[11C]CHDI-180RAggregated mutant huntingtinHuntington’s diseasemHTTPET imaging

Identifiers

PMID40527969

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.